GMED
Globus Medical·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GMED
Globus Medical, Inc.
A leading musculoskeletal solutions company
Healthcare Equipment and Supplies
--
08/03/2012
New York Stock Exchange
5,300
12-31
Common stock
2560 General Armistead Avenue
, Audubon
, PA 19403-5214
--
Globus Medical, Inc., was incorporated in Delaware in March 2003. As a medical device manufacturing company, Globus is fully focused on the design, development and commercialization of its products, which can promote the recovery of patients with spinal diseases. Globus products are divided into two categories, namely innovation and integration and disruptive technology.
Earnings Call
Q1/2025
Estimate EPS0.74
Actual EPS0.68
Estimate Revenue625.90M
Actual Revenue598.10M
Contradictions in Focus: Analyzing Globus Medical's 2025 Q1 Earnings Call Insights on Spine Market and Nevro Integration
May 19,2025 11:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GMED has released its 2025 Q3 earnings. EPS was reported at 1.18, versus the expected 0.77, beating expectations. The chart below visualizes how GMED has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GMED has released its 2025 Q3 earnings report, with revenue of 769.05M, reflecting a YoY change of 22.91%, and net profit of 118.97M, showing a YoY change of 129.50%. The Sankey diagram below clearly presents GMED's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
